RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
RS-0139, A NOVEL TUMOR-TARGETED DELIVERY OF DOCETAXEL, WITH POTENT ANTI-TUMOR ACTIVITY IN A BROAD SPECTRUM OF TUMOR CELL LINES AND XENOGRAFT MODELS ESMO TAT 2023, 6-8 March, Paris 🡕 Abstract ⤓ Poster Presenters Gulsah Nomak Citation Annals of Oncology (2023) 8 (1suppl_2): 100898-100898. 10.1016/esmoop/esmoop100898 Authors G. Nomak1, M. Karacivi2, S. Kutlu Ozkaya2, U. Valeria3, B. Sumer […]
